Bristol Historical Balance Sheet

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Trend analysis of Bristol Myers Squibb balance sheet accounts such as Receivables of 8.3 B, Accounts Payable of 2.6 B or Total Assets of 140.2 B provides information on Bristol Myers total assets, its liabilities, and its equity, which is the actual value of Bristol Myers Squibb to its prevalent stockholders. By breaking down trends over time using Bristol Myers balance sheet statements, investors will see what exactly the company owned and what it owed to creditors or other parties at the end of each accounting year. Financial Statement Analysis is much more than just reviewing and breaking down Bristol Myers Squibb prevalent accounting reports in order to predict its past. Macroaxis encourages investors to analyze financial statement over time for various trends across multiple indicators and accounts to determine whether Bristol Myers Squibb is a good buy for the upcoming year. Continue to Trending Equities.

Search Historical Statements


About Bristol Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Bristol Myers Squibb at a specified time, usually calculated after every quarter, six months, or one year. Bristol Myers Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bristol Myers and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bristol currently owns. An asset can also be divided into two categories, current and non-current.

Bristol Myers Balance Sheet Chart

Bristol Myers Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Bristol Myers Squibb uses and utilizes its capital. It also shows what exactly a company owns and owes. Bristol Myers Shareholders Equity is fairly stable at the moment as compared to the past year. Bristol Myers reported Shareholders Equity of 51.6 Billion in 2019. Goodwill and Intangible Assets is likely to grow to about 93.3 B in 2020, whereas Accumulated Other Comprehensive Income is likely to drop (1.6 B) in 2020.
Add Fundamental

Total Assets

Total assets refers to the total amount of Bristol Myers assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bristol Myers Squibb books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; Investments; Goodwill and Intangible Assets; Property Plant and Equipment Net; Tax Assets and Trade and Non Trade Receivables.

Current Assets

Current assets of Bristol Myers Squibb include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Bristol Myers. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Assets Non Current

Amount of non-current assets; for companies that operate a classified balance sheet. Calculated as the different between Total Assets Total Assets and Current Assets Current Assets.

Cash and Equivalents

A component of Total Assets representing the amount of currency on hand as well as demand deposits with banks or financial institutions.
Most accounts from Bristol Myers balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.Bristol Myers Shareholders Equity is fairly stable at the moment as compared to the past year. Bristol Myers reported Shareholders Equity of 51.6 Billion in 2019. Goodwill and Intangible Assets is likely to grow to about 93.3 B in 2020, whereas Accumulated Other Comprehensive Income is likely to drop (1.6 B) in 2020.
 2017 2018 2019 2020 (projected)
Receivables5.09 B5.35 B7.68 B8.29 B
Inventories1.17 B1.2 B4.29 B4.63 B

Bristol Myers balance sheet Correlations

Click cells to compare fundamentals   Check VolatilityBacktest Portfolio

Bristol Myers Account Relationship Matchups

Bristol Myers balance sheet Accounts

2014201520162017201820192020 (projected)
Inventories1.56 B1.22 B1.24 B1.17 B1.2 B4.29 B4.63 B
Receivables2.32 B3.16 B4.01 B5.09 B5.35 B7.68 B8.29 B
Accounts Payable2.49 B1.56 B1.66 B2.25 B1.89 B2.44 B2.56 B
Accumulated Other Comprehensive Income(2.42 B)(2.47 B)(2.5 B)(2.29 B)(2.76 B)(1.52 B)(1.64 B)
Total Assets33.75 B31.75 B33.71 B33.55 B34.99 B129.94 B140.2 B
Current Assets14.61 B10.41 B13.7 B14.85 B17.72 B29.35 B24.48 B
Assets Non Current19.14 B21.33 B20 B18.7 B17.27 B100.59 B108.53 B
Cash and Equivalents5.57 B2.38 B4.24 B5.42 B6.91 B12.35 B13.32 B
Cash and Equivalents USD5.57 B2.38 B4.24 B5.42 B6.91 B12.35 B13.32 B
Total Debt7.83 B6.69 B6.71 B7.96 B7.35 B46.73 B50.42 B
Debt Current590 M139 M992 M987 M1.7 B3.35 B3.61 B
Debt Non Current7.24 B6.55 B5.72 B6.97 B5.65 B43.39 B46.81 B
Total Debt USD7.83 B6.69 B6.71 B7.96 B7.35 B46.73 B50.42 B
Deferred Revenue1.52 B1.94 B1.59 B1.31 B537 M483.3 M496.02 M
Shareholders Equity14.85 B14.27 B16.18 B11.74 B14.03 B51.6 B55.67 B
Shareholders Equity USD14.85 B14.27 B16.18 B11.74 B14.03 B51.6 B55.67 B
Goodwill and Intangible Assets8.78 B8.3 B8.26 B8.07 B7.63 B86.46 B93.28 B
Inventory1.56 B1.22 B1.24 B1.17 B1.2 B4.29 B4.63 B
Investments6.27 B6.54 B4.83 B3.87 B3.62 B3.81 B3.97 B
Investments Current1.86 B1.89 B2.11 B1.39 B1.85 B3.05 B2.67 B
Investments Non Current4.41 B4.66 B2.72 B2.48 B1.77 B767 M787.18 M
Total Liabilities18.77 B17.32 B17.36 B21.7 B20.86 B78.25 B84.42 B
Current Liabilities8.46 B8.02 B8.84 B9.56 B10.65 B18.3 B15.18 B
Liabilities Non Current10.3 B9.31 B8.52 B12.14 B10.21 B59.94 B64.67 B
Trade and Non Trade Payables2.49 B1.56 B1.66 B2.25 B1.89 B2.44 B2.52 B
Property Plant and Equipment Net4.42 B4.41 B4.98 B5 B5.03 B6.25 B6.15 B
Trade and Non Trade Receivables3.39 B4.3 B5.54 B6.3 B5.75 B7.68 B6.67 B
Accumulated Retained Earnings Deficit32.54 B31.61 B33.51 B31.16 B34.06 B34.47 B37.01 B
Tax Assets2.56 B2.84 B3 B1.61 B815 M510 M523.42 M
Tax Liabilities822 M1.31 B1.12 B3.78 B19 M6.45 B6.96 B
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page